Loading

How to reduce the current fragility of cell & gene therapy raw materials supply chains?

20 Jan 2027
Theatre 6
CGT Connect

An interactive discussion examining the vulnerabilities and challenges affecting raw material supply chains for cell and gene therapies. The session will explore the factors contributing to supply chain fragility, including supplier concentration, material availability, quality and consistency, lead times and the challenges of sourcing specialised materials for advanced therapy manufacturing.

Bringing together perspectives from developers and raw material specialists, the discussion will consider how companies can better manage supply chain risks, evaluate and qualify suppliers, identify alternative sourcing strategies and build more resilient procurement approaches. Participants will have the opportunity to share experiences and discuss practical steps towards securing reliable raw material supply as manufacturing requirements evolve and programmes scale.

Chairperson
Lili Belcastro, Associate Director - Bristol Myers Squibb
Basak Clements, Founder & Senior Scientific Advisor - biomatria
Speakers
Amit Joshi, Senior Director, Strategic Sourcing - Iovance Biotherapeutics

Topic

Manufacturing CMC & Supply Chain

Persona

Biotech,Logistics & Distribution Partners,Pharma,Service Providers (CDMOs CROs & Suppliers),Tools tech & equipment providers